An obscure Roche dataset reignites the Tigit space, and sends up Arcus, Compugen and Iteos.
Apparently knockout ovarian cancer data put Immunogen’s Elahere on track for full approval, a risk Sutro investors have decided to ignore.
Important ovarian cancer data are ahead for Immunogen and Mersana, while Disc Medicine eyes a rare metabolic disorder.
Zymeworks, Profoundbio, Elucida and Immunogen itself piggyback on Elahere’s success to develop a better antibody-drug conjugate.
The group reckons it can target twice as many ovarian cancer patients, but an important disclosure shows that its case it not clear-cut.
Moderna, Biomarin and Daiichi Sankyo will begin 2023 with important data reveals.
Meanwhile, there was bad blood between cell therapy players and their investors.
The US conditional approval pathway has enjoyed years of expansion, but now the FDA is trying to put the toothpaste back into the tube.